Stanford University
Showing 461-470 of 511 Results
-
Henry Lowood
Harold C. Hohbach Curator - History of Science & Technology; Film & Media, Humanities Resource Group
Current Role at StanfordHarold C. Hohbach Curator, Stanford Libraries
-
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
-
Prashant Loyalka
Associate Professor of Education and Senior Fellow at the Freeman Spogli Institute for International Studies
Current Research and Scholarly InterestsPrashant's research focuses on examining/addressing inequalities in the education of youth and on understanding/improving the quality of education received by youth in a number of countries including China, India, Russia, and the United States. In the course of addressing educational inequalities, Prashant examines the consequences of tracking, financial and informational constraints, as well as social and psychological factors in highly competitive education systems. His work on understanding educational quality is built around research that assesses and compares student learning in higher education, high school and compulsory schooling. He furthermore conducts large-scale evaluations of educational programs and policies that seek to improve student outcomes.
-
Bingwei Lu
Professor of Pathology
Current Research and Scholarly InterestsWe are interested in understanding how neural stem cells balance their self-renewal and differentiation and how deregulation of this process can result in brain tumor. We are also interested in mechanisms of neurodegeneration in Alzheimers and Parkinsons diseases. We are using both Drosophila and mammalian models to address these fundamental questions.
-
Lu,Guolan
Assistant Professor of Urology
Current Research and Scholarly InterestsThe Lu Lab develops and integrates AI, spatial multi-omics, and advanced imaging to understand and model how cells, tissues, and therapeutic agents interact in their native spatial context, and how these interactions drive disease progression and treatment response.
-
Janice Lu
Clinical Professor, Medicine - Oncology
BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).
Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care. -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.
